ERBB2 and breast carcinoma: In addition, previous studies in breast cancer patients revealed that VISTA leads to a local immunosuppressive microenvironment [44,51,52,53], strengthening the results reported in this study, and the systemic immunosuppressive status described in queens diagnosed with HER2-positive tumors [6,19,22].